Off-Label With Altasciences

What does it really take to build a successfulbiotech? From addressing unmet medical needs, securing investor backing and reaching critical value inflection points, to navigating acquisitions and building a company positioned for long-term success, there’s a delicate balance to strike between science and finance. On the latest Off-Label With Altasciences , host Lisa Sanford is joined by James Mack...

Model-informed drug development (MIDD) capitalizes on past data points with predictive modeling to accelerate timelines and address challenges earlier. It also presents a slew of other potential advantages, such as shrinking the data-access gap between large pharma and small biotechs, and reducing study subjects in both nonclinical and clinical trials. So, what does this mean for the drug developm...

Host Lisa Sanford is joined by Neil Spooner (PCSIG), Katty Wan (Pfizer), Enaksha Wickremsinhe (Gates Medical Research Institute), and Jeff Plomley (Altasciences) to discuss microsampling and the role it plays in a patient-centric sampling approach. With reduced sample volume, as well as the ability to provide additional options and convenience to patients, this episode showcases the “big” potentia...

Automation? Personalized medicine? A shifting talent pool? Dive into the rapidly changing world of drug development and listen to experts give their boldest predictions for the future of CROs. Host Lisa Sanford is joined by colleagues from Altasciences, Marie-Hélène Raigneau, CEO; Steve Mason, Co-COO; and Dr. Gaetano Morelli, Executive Vice President Medical Affairs and Chief Medical Officer; as t...

Learn about the multi ple benefits that incorporating a multi-site approach can provide in early-phase clinical research, the “red and green flags” to look out for when working with a CRO, the importance of the “non-data stuff.” Host Lisa Sanford is joined by Kat Connors, Director, Multi-Site Clinical Trial and Strategic Operations at Altasciences, as they discuss the momentum growing behind using...

We’ve got some exciting news to share… We’re launching a new podcast called Off-Label! Host Lisa Sanford is peeling back the label on drug development to discuss trending topics and new advancements alongside industry experts—offering a candid insider’s perspective. Coming soon!